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Abstract
We present a case that highlights the difficulties with diagnosis and the dangers of occupational 
allergic sinusitis and asthma left unrecognized. We describe the case history of a man who 
experienced work-related symptoms 1 year after beginning work as a cheesemaker at a creamery, 
and whose respiratory symptoms progressively worsened over 16 years before an occupational 
cause of his asthma was identified. His initial discrete episodes of sinusitis and acute bronchitis 
evolved into persistent asthma of increasing severity with exacerbations requiring repeated 
emergency room treatment. The case described in our report emphasizes the importance of 
clinician diagnosis of OA, and subsequent removal from exposure, such that asthma severity does 
not progress to near-fatal or fatal asthma in the sensitized worker. As demonstrated by this case 
report, identification of an occupational cause of asthma relies on a high degree of suspicion and 
excellent detective work by the clinician.
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1 INTRODUCTION
Occupational asthma is the most widely reported occupational lung disease. Previous studies 
suggest that 5–25% of adult asthma cases are caused or exacerbated by occupational 
exposures.1–4 A recent review article by Tarlo and Lemiere4 emphasized that occupational 
asthma “outcomes are best when the diagnosis is established early, the exposure is stopped, 
and the asthma is not yet severe.” Because the list of sensitizing or irritant agents that initiate 
asthma is extensive and new asthmagens are discovered each year, a clinician’s ability to 
identify the causal workplace asthmagen relies upon a high degree of suspicion and 
excellent detective work. Failure to identify a causal agent and eliminate exposure can result 
in increased disease severity, substantial morbidity, or even death.
We present a case that highlights the difficulties with diagnosis and the dangers of 
occupational allergic sinusitis and asthma left unrecognized. Although asthma from locust 
bean gum (LBG) exposure has been previously reported, to our knowledge, this is the first 
severe case.5–7 LBG, also known as Carob bean gum, is one of several seed-derived 
vegetable gums and is derived from grinding the endosperms from the seeds of Carob trees, 
which fall under the family Fabaceae.8 LBG is used as a thickening and gelling agent in 
food production,8 and recently has also been used in drug delivery systems in 
pharmaceutical industries, and in tissue scaffolds in biomedical applications.9,10 Often sold 
and used as a powder,8 LBG can be aerosolized during various occupational tasks in food 
production, pharmaceutical, or biomedical industries. Approximately 2.9 tons of LBG were 
imported by the United States in 2011 alone.11 We describe the case history of a man who 
began with symptoms 1 year after beginning work as a cheesemaker at a creamery, and 
experienced progressively severe respiratory symptoms over 16 years. His initial discrete 
episodes of sinusitis and acute bronchitis evolved into persistent asthma of increasing 
severity punctuated by exacerbations requiring repeated Emergency Room treatment despite 
daily controller inhaler therapy and courses of corticosteroids. His severe dyspnea, exercise 
limitation, and chest pain led to referral for cardiac disease, with eventual cardiac 
catheterization excluding coronary artery disease. Peak flow monitoring that demonstrated 
improved peak flow rates during a work holiday provided an impetus to refer him for 
evaluation of suspected occupational asthma. Specialty evaluation, including careful review 
of his work history and safety data sheets from his workplace, led to allergy testing which 
confirmed LBG as the cause of his sinusitis and asthma. A recommendation for medical 
removal ended his need for repeated emergency room care of his asthma although he 
continues with severe persistent asthma requiring daily medication and work 
accommodations.
The case of severe occupational sinusitis and concomitant asthma described here supports 
the united allergic airway hypothesis.12 Additionally, this case highlights the importance of 
identifying an Occupational Sentinel Health Event early in the disease process such that 
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controls designed to mitigate exposure may be implemented13 thus avoiding progression to 
severe disease. This case further emphasizes the value of peak flow monitoring connected to 
prolonged work absences as a means of screening for occupational asthma, and of obtaining 
a thorough work history, and pursuing information about workplace exposures to establish a 
diagnosis early when the airway disease is not yet severe.
2 CASE REPORT
A 35-year-old man with no significant past medical history began working at a creamery in 
1986. He held several ancillary positions before becoming directly involved in 
cheesemaking in 1995 (Fig. 1). His tasks as a cheesemaker’s assistant and later as a cheese-
room processor included obtaining and measuring finely powdered locust bean gum (LBG) 
from bulk containers in storage areas and adding the LBG to cream cheese mixtures. In early 
1996, he presented with the complaint of wheezing upon exposure to cold air. Subsequently, 
he was seen repeatedly over the course of 8 years for recurrent episodes of acute respiratory 
illness, with listed diagnoses including rhinitis, sinusitis, acute bronchitis, and cold-induced 
asthma. Therapy gradually intensified from brief courses of a short-acting beta-agonist, an 
antitussive, and antibiotics in 1996, to include oral corticosteroids, first prescribed in 1998; 
nasal steroids, first prescribed in 2000; a long-acting beta-agonist, first prescribed in 2001; 
and an inhaled steroid, first prescribed in 2003 (Fig. 1).
In 2003, chronic symptomatic sinusitis prompted functional endoscopic sinus surgery with 
pathology demonstrating increased eosinophils and inflammatory polyps. The surgery was 
complicated by post-operative hemorrhage requiring air transport to a tertiary care medical 
center and red cell transfusion. Hematologic evaluation revealed a disorder of platelet 
function which impairs hemostasis. A prolonged at-home convalescence was required to 
recover from these events, during which he noted complete resolution of his respiratory 
symptoms. He was treated with daily nasal steroids post-operatively and returned to work, 
but did not require inhaled corticosteroids or beta-agonists for 18 months (Fig. 1). After his 
return to work, his acute and chronic upper and lower respiratory symptoms gradually 
returned, as did the eosinophilia, peaking at 800 in 2010. Initial pulmonary consultation 
indicated possible mild allergic triggers, but testing for workplace allergy was not pursued. 
Despite ongoing therapy with multiple inhalers, courses of antibiotics and oral steroids, and 
addition of a leukotriene receptor antagonist, his asthma control score (ACT) of 16 (ACT 
scores range 5–25; score of >19 indicates control), indicated his asthma was not under 
control. Additionally, spirometry showed marked reversible air flow obstruction with 
hyperinflation and air trapping (Table 1). During this period, he had visited the Emergency 
Department multiple times for dyspnea, chest pain, and marked exercise limitation, leading 
to referral for cardiology consultation.
He was referred in 2011 to a second pulmonologist. Discussion of possible symptom 
triggers revealed that his eyes and skin would sometimes itch at work and he had difficulty 
breathing when performing tasks that involved scooping a powder and adding the powder to 
cheese mixtures. Consultation with a colleague with training in occupational medicine led to 
immediate initiation of portable peak expiratory flow rate monitoring. Incidentally, he was 
scheduled for a 10-day holiday work break later that month. Evaluation in January showed 
Hawley et al. Page 3
Am J Ind Med. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
that when he was away from work his peak expiratory flow improved from 200 lpm to 400 
lpm. Referral to a pulmonologist with training in occupational medicine led to further 
discussion of his work tasks and review of Safety Data Sheets (SDS’s) requested from the 
workplace identified the powder as LBG. A subsequent flurorescent enzyme-linked 
immunosorbent assay (ImmunoCAP, Thermo Fisher Scientific-Phadia AB, Uppsala, 
Sweden) quantified high levels (85 kU per L) of LBG specific IgE (Table 2). Consequently, 
the patient was removed from job duties that required the use of LBG in mid-2012. At that 
point he had worked for 16 years as a cheesemaker at a creamery.
His need for emergency room care ended as soon as he was removed from contact with the 
LBG powder. Additionally, his FEV1 increased by almost a liter and a half over the next 2 
years (Table 1). Although his ACT scores improved, he continued to need daily inhaler 
therapy with inhaled corticosteroids and long acting beta agonists as well as the leukotriene 
modifier. A cardiac catheterization showed no coronary artery disease, and he returned to 
being able to exercise vigorously. He required inguinal hernia repair, a condition that 
developed during the years he was having severe coughing.
Because his tasks as a cheesemaker required the use of LBG powder, he had to be removed 
from work in the cheese room and was forced to bid for other jobs. His subsequent 
relocation, however, included job duties that required the use of cleaning chemical irritants 
and sensitizers. Although LBG was identified as the primary sensitizer, he had developed 
generalized airway reactivity to chemicals. Cleaning tasks associated with symptoms 
included floor stripping and surface cleaning with quaternary ammonium compounds. 
Subsequently, he was reassigned to custodial tasks in office areas which did not require the 
use of these triggers and his symptoms improved.
3 DISCUSSION
Identification of an Occupational Sentinel Health Event has important preventive 
implications, for both a patient and a patient’s coworkers.13 However, as occurred in this 
case, occupational respiratory disease that occurs outside of traditional industrial settings 
can be difficult to recognize, and can delay diagnosis and appropriate therapy. Previous 
studies suggest that occupational asthma (OA) is a common, but often unrecognized 
disease.14,15 Occupational upper airway disease is often more prevalent than OA16 and 
several studies suggest that rhinosinusitis may precede or occur concomitantly with 
asthma.16,17 The common airway hypothesis suggests that occupational upper airway 
disease should alert a clinician to a risk for lower airway involvement.16–19 Despite 
associations between occupational rhinosinustis and OA, occupational upper airway disease 
is frequently not regarded as serious.18 In this case, the severity of the eosinophilic sinusitis 
led to a need for surgery with a serious post-operative complication. The patient was 
temporarily able to be taken off daily asthma medications during his time away from work 
while he recovered from surgery. Upon return to work, his acute and chronic upper and 
lower airway symptoms gradually returned. Nine years passed after his sinus surgery with 
recurrence and progression to chronic rhinosinusitis and severe persistent asthma before his 
occupational disease was diagnosed and he was removed from exposure. Recognition of 
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occupational upper airway disease may allow a clinician to recommend preventive measures 
when the asthma is not yet severe and avert this progression.
When OA is suspected, serial peak expiratory flow measurements taken during times at 
work and times away from work can be used to confirm a work-related pattern.20–22 If OA is 
confirmed using this approach, the exposure associated with OA may still be difficult to 
readily identify. Parhar et al14 observed that clinicians most readily recognized OA when the 
asthma was caused by an asthmagen with which they are already familiar. Additionally, time 
constraints can preclude clinicians’ obtaining a thorough work history.14,23 Clinicians can 
enlist the help of trained occupational health nurses or nurse practitioners who can assist in 
obtaining a comprehensive occupational history.24 Clinicians should consider consulting 
with occupational hygienists familiar with the workplace processes and practices.24 
Workplaces where known asthmagens are used may have occupational health programs 
aimed at the early identification of incident cases. Referral to an occupational medicine 
specialist may also be warranted. The medical records for this case indicated occasional 
comments about his job, but no knowledge of the specific exposure. Although the process of 
identifying the potential causal workplace agent demands clinician awareness and time, the 
consequences of unrecognized asthma and a delayed diagnosis can be fatal. Furthermore, 
unrecognized and uncontrolled asthma results in a heavy public health burden and 
economical cost. In 2010, there were 1.8 million asthma-related Emergency Department 
visits and 439 000 asthma hospitalizations in the United States alone25 and previous studies 
highlight that an estimated 16.3% of all cases of adult-onset asthma are caused by 
occupational exposure.4,26
OA is complex in that it can be caused by four mechanisms, to include (1) IgE-mediated 
sensitization to an allergen; (2) non-IgE-mediated sensitization; (3) irritant-induced asthma 
or reactive airways dysfunction syndrome; or (4) a combination of sensitization and irritant-
induced mechanisms.27,28 Of these mechanisms, specific diagnostic immunologic tests for 
IgE or IgG sensitization are available and can identify many, but not all, high-molecular 
weight asthmagens. On the other hand, few immunologic tests are available for low-
molecular weight asthmagens. When specific diagnostic tests are unavailable, the ability to 
link an occupational exposure to asthma is only as effective as the clinician’s ability to 
identify a potential workplace exposure that is associated with OA and to perform serial 
clinical assessments.
Workplace safety data sheets (SDS’s) provide helpful information about chemical irritants 
and toxicants and can alert a clinician to potential occupational respiratory hazards.20 
However, SDS’s are not always utilized by a clinician. Indeed, as noted in this case report, 
16 years of work-related symptoms elapsed before a pulmonologist with occupational 
medicine training reviewed SDS’s from his workplace for possible exposures. Furthermore, 
as highlighted by Bernstein, sole reliance upon the health hazard information presented in 
SDS’s may not be sufficient.29 We note that in this case, locust bean gum was evident on the 
SDS; however, in other cases chemical names and formulas may be omitted from SDS’s if 
the manufacturer deems the information trade secret. Additionally, companies are not 
required to state which products may be respiratory sensitizers or share documented clinical 
information relevant to occupational lung disease.29 A clinician may need to contact the 
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chemical manufacturer and inquire about omitted information in the SDS. Another useful 
resource is asthmagen information published by the Association of Occupational and 
Environmental Clinics (AOEC). As Bernstein emphasizes, clinicians need to be persistent 
when seeking this information so as to avoid an unnecessary delay in diagnosis.29
Delays in diagnosis can be fatal for OA. We describe here a case that resulted in severe and 
refractory asthma, a group that is at increased risk for fatal asthma.30 Fatal OA has been 
described for workers in wide-ranging work environments to include food industries,31 
farming,32 pharmaceutical and nutraceutical industries,33,34 cosmetology,35 chemical 
factories,36 autobody industries,37 metal foundries,38 and printing industries.39 Fatal asthma 
cases documented in the previous studies were described in workers that ranged from 26 to 
75 years of age, and the delay between the onset of occupational asthma symptoms and 
death ranged from 6 months to 20 years. The previously described fatal asthma cases 
emphasize the grave consequences of failure to reduce or eliminate exposure in 
unrecognized OA.
Agents associated with previous fatal OA cases include flour dust, papain powder, shark 
cartilage dust, hair dye, bicycloheptadiene dibromide, acacia gum, and isocyanates. Of these 
agents, only isocyanates and flour dust have US occupational exposure limits, despite 
documented fatal outcomes. Moreover, it is important to note that even when occupational 
exposure limits do exist, the exposure limits may not be protective for a worker that has 
become sensitized.34,40 Clinician diagnosis of OA and subsequent exposure reduction or 
removal from exposure are necessary protective measures to ensure that asthma severity 
does not progress to near-fatal or fatal asthma in the sensitized worker. However, as 
demonstrated by this case report, identification of an occupational cause of asthma relies on 
excellent detective work by the clinician.
We describe here a worker sensitized to LBG with occupational sinusitis and asthma that 
remained undiagnosed for the 16 years that the patient reported increasingly severe 
respiratory symptoms. Despite his development of sinusitis and intermittent asthma within a 
year of being transferred to cheese-maker duties, the cause of his OA was not identified until 
persistent uncontrolled asthma had developed including multiple Emergency Department 
visits for severe asthma. In summary, this case report emphasizes the importance that 
clinicians (1) have an elevated index of suspicion for occupational sinusitis and OA, 
especially in patients presenting with an accelerating disease history; (2) obtain a thorough 
occupational history (3); utilize peak expiratory flow measurements to identify a work-
related pattern; (4) consult with occupational health professionals familiar with workplace 
processes and practices; (5) use workplace Safety Data Sheets and other information sources 
to identify potential asthmagens; and (6) when possible, utilize immunologic testing that 
includes suspected workplace asthmagens such that a diagnosis and removal from exposure 
may be established early when the asthma is not yet severe.
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FIGURE 1. 
Locust bean gum (LBG) exposure and symptoms, medications prescribed, medical 
procedures, and eosinophil count in a cheese-maker with unrecognized occupational 
etiology for sinusitis and asthma. ACT indicates asthma control score. SABA and LABA 
indicate short-acting beta agonist and long-acting beta agonists, respectively. Prn indicates 
medications that were used on an as needed basis
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TABLE 2
Respiratory allergen profile results from fluorescent enzyme immunoassay (Immuno-CAP® [Thermo Fisher 
Scientific-Phadia AB])
Allergen Value (kU/L) Classa
Horse dander <0.35 0
Cat dander <0.35 0
Dog dander <0.35 0
Dermatophagoides farina <0.35 0
Cockroach 0.89 2
Dermatophagoides petronyssinus 0.37 1
Bermuda grass <0.35 0
Timothy grass <0.35 0
Penicillum notatum <0.35 0
Aspergillus fumigatus <0.35 0
Alternaria alternata <0.35 0
Maple (box elder) <0.35 0
Mountain cedar <0.35 0
Oak <0.35 0
Birch <0.35 0
Elm <0.35 0
Walnut tree <0.35 0
Sycamore <0.35 0
Cottonwood <0.35 0
White ashes <0.35 0
Common ragweed <0.35 0
Mugwort <0.35 0
Rough pigweed <0.35 0
Sheep sorrel <0.35 0
Locust bean gum 85 5
Total IgE 283 –
aClass designations are classified by IgE kU/L. Class designations of 0–6 indicate IgE concentrations of <0.35, 0.35–0.7, 0.71–3.5, 3.51–17.5, 
17.51–50, 50.01–100, or greater than 100 kU/L, respectively.
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